zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2013-10-4-9zdor-1429Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESСЕРДЕЧНО-СОСУДИСТАЯ ПАТОЛОГИЯ У ЖЕНЩИН: РИСКИ И ШАНСЫ (обзор литературы)CARDIOVASCULAR PATHOLOGY IN WOMEN: RISKS AND CHANCES (literature review)БарбаровичА. С.BarbarovichA. S.noemail@neicon.ruСаливончикД. П.SalivonchikD. P.noemail@neicon.ruГомельский государственный медицинский университетGomel State Medical University201328122013045358Copyright © Барбарович А.С., Саливончик Д.П., 20132013Барбарович А.С., Саливончик Д.П.Barbarovich A.S., Salivonchik D.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/1429

Традиционный взгляд на кардиоваскулярную патологию как прерогативу мужской части населения планеты себя не оправдал. В женской популяции сердечно-сосудистые заболевания также являются главной причиной, формирующей смертность, но факторы риска кардиоваскулярной патологии у мужчин и женщин существенно различаются. В обзоре представлены основные патогенетические механизмы развития сердечно-сосудистой патологии, в основном ишемической болезни сердца у женщин.

The traditional view on cardiovascular pathology being the prerogative of the male population of the planet has not justified itself. Cardiovascular diseases also are the main cause of death in the female population, but the risk factors for cardiovascular pathology in men and women essentially differ. The review covers the basic pathogenetic mechanisms of development of cardiovascular pathology, basically, ischemic disease of heart in women.

кардиометаболический рискишемическая болезнь сердцаcardiometabolic riskischemic heart diseaseReferencesАронов, Д. М. Методика оценки качества жизни больных сердечно-сосудистыми заболеваниями / Д. М. Аронов, В. М. Зайцев // Кардиология. -- 2002. -- №5. -- С. 92-95.Аронов, Д. М. Методика оценки качества жизни больных сердечно-сосудистыми заболеваниями / Д. М. Аронов, В. М. Зайцев // Кардиология. -- 2002. -- №5. -- С. 92-95.Гиляревский, С. Р. // Сердце. - 2006. - Т. 5, № 7. - С. 340-345.Гиляревский, С. Р. // Сердце. - 2006. - Т. 5, № 7. - С. 340-345.Беленкова, Ю. Н. Кардиология. Национальное руководство / Ю. Н. Беленкова, Р. Г. Оганова. - М.: ГЭОТАР-Медиа, 2007. - С. 43-39.Беленкова, Ю. Н. Кардиология. Национальное руководство / Ю. Н. Беленкова, Р. Г. Оганова. - М.: ГЭОТАР-Медиа, 2007. - С. 43-39.Eckel, R. H. The metabolic syndrome / R. H. Eckel, S. M. Grundy, P. Z. Zimmet // Lancet. - 2005. - Vol. 365. - P. 1415-1428.Eckel, R. H. The metabolic syndrome / R. H. Eckel, S. M. Grundy, P. Z. Zimmet // Lancet. - 2005. - Vol. 365. - P. 1415-1428.Hu, G. DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes / G. Hu // Diabetologia. - 2003. - Vol. 46. - P. 608-617.Hu, G. DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes / G. Hu // Diabetologia. - 2003. - Vol. 46. - P. 608-617.Estrogen plus progestin and the risk of coronary heart disease / J. E. Manson [et al.] // N. Engl. J. Med. - 2003. - Vol. 349. - P. 523-534.Estrogen plus progestin and the risk of coronary heart disease / J. E. Manson [et al.] // N. Engl. J. Med. - 2003. - Vol. 349. - P. 523-534.Hajjar, I. Trends in prevalence, awareness, treatment, and control of hypertension in the United States 1988-2000 / I. Hajjar, T. A. Kotchen // JAMA. - 2003. - Vol. 290. - P. 199-206.Hajjar, I. Trends in prevalence, awareness, treatment, and control of hypertension in the United States 1988-2000 / I. Hajjar, T. A. Kotchen // JAMA. - 2003. - Vol. 290. - P. 199-206.Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials / J. A. Staessen [et al.] // Hypertens Res. - 2005. - Vol. 28. - P. 385-407.Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials / J. A. Staessen [et al.] // Hypertens Res. - 2005. - Vol. 28. - P. 385-407.Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies / S. Lewington [et al.] // Lancet. - 2002. - Vol. 360. - P. 1903-1913.Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies / S. Lewington [et al.] // Lancet. - 2002. - Vol. 360. - P. 1903-1913.Reckelhoff, J. F. Basic research into the mechanisms responsible for postmenopausal hypertension / J. F. Reckelhoff // Int J Clin Pract. - 2004. - Vol. 58. (Suppl. 139). - P 13-19.Reckelhoff, J. F. Basic research into the mechanisms responsible for postmenopausal hypertension / J. F. Reckelhoff // Int J Clin Pract. - 2004. - Vol. 58. (Suppl. 139). - P 13-19.Struthers, A. D. Review of aldosterone- and angiotensin II-induced target organ damage and prevention / A. D. Struthers, T. M. MacDonald // Cardiovasc Res. - 2004. - Vol. 61. - P. 663-670.Struthers, A. D. Review of aldosterone- and angiotensin II-induced target organ damage and prevention / A. D. Struthers, T. M. MacDonald // Cardiovasc Res. - 2004. - Vol. 61. - P. 663-670.The assotiation between the rennin-angiotensin-aldosterone system and arterial stiffness in young healthy subects / Y. Shapiro [et al.] // Clin Endocrinol. - 2008. - Vol. 68. - P. 510-512.The assotiation between the rennin-angiotensin-aldosterone system and arterial stiffness in young healthy subects / Y. Shapiro [et al.] // Clin Endocrinol. - 2008. - Vol. 68. - P. 510-512.Schmidt, B.M.W. Aldosterone induced cardiac damage focus on blood pressure independent effects / B. M. W. Schmidt, R. E. Schmieder // Am J Hypertens. - 2003. - Vol. 16. - P. 80-86.Schmidt, B.M.W. Aldosterone induced cardiac damage focus on blood pressure independent effects / B. M. W. Schmidt, R. E. Schmieder // Am J Hypertens. - 2003. - Vol. 16. - P. 80-86.Mahmud, A. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension / A. Mahmud, J. Feely // Am J Hypertens. - 2005. - Vol. 18. - P. 50-55.Mahmud, A. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension / A. Mahmud, J. Feely // Am J Hypertens. - 2005. - Vol. 18. - P. 50-55.Evidence-based guidelines for cardiovascular disease prevention in women / L. Mosca [et al.] // Circulation. - 2004. - Vol. 109. - P. 672-693.Evidence-based guidelines for cardiovascular disease prevention in women / L. Mosca [et al.] // Circulation. - 2004. - Vol. 109. - P. 672-693.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial / P. S. Sever [et al.] // Lancet. - 2003. - Vol. 361. - P. 1149-1158.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial / P. S. Sever [et al.] // Lancet. - 2003. - Vol. 361. - P. 1149-1158.Walsh, J. M. E. Drug treatment of hyperlipidemia in women / J. M. E. Walsh, M. Pingnone // JAMA. - 2004. - Vol. 291. - P. 2243-2252.Walsh, J. M. E. Drug treatment of hyperlipidemia in women / J. M. E. Walsh, M. Pingnone // JAMA. - 2004. - Vol. 291. - P. 2243-2252.Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial / M. J. Bolland [et al.] // BMJ. - 2008. - Vol. 336. - P. 262-266.Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial / M. J. Bolland [et al.] // BMJ. - 2008. - Vol. 336. - P. 262-266.Feasibility of treating prehypertension with an angiotensin-receptor blocker / S. Julius [et al.] // N Engl J Med. - 2006. - Vol. 354. - P. 1685-1697.Feasibility of treating prehypertension with an angiotensin-receptor blocker / S. Julius [et al.] // N Engl J Med. - 2006. - Vol. 354. - P. 1685-1697.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report / A. V. Chobanian [et al.] // JAMA. - 2003. - Vol. 289. - P. 2560-2572.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report / A. V. Chobanian [et al.] // JAMA. - 2003. - Vol. 289. - P. 2560-2572.Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome / N. D. Wong [et al.] // Am J Cardiol. - 2003. - Vol. 91. - P. 1421-1426.Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome / N. D. Wong [et al.] // Am J Cardiol. - 2003. - Vol. 91. - P. 1421-1426.Guidelines Subcommittee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension // J. Hypertens. - 2003. - Vol. 21. - P. 1011-1153.Guidelines Subcommittee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension // J. Hypertens. - 2003. - Vol. 21. - P. 1011-1153.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendro-flumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial / B. Dahlöf [et al.] // Lancet. - 2005. - Vol. 366. - P. 895-906.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendro-flumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial / B. Dahlöf [et al.] // Lancet. - 2005. - Vol. 366. - P. 895-906.Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure / W.H. Tang [et al.] // J Am Coll Cardiol. - 2002. - Vol. 39. - P. 70-78.Neurohormonal and clinical responses to high-versus low-dose enalapril therapy in chronic heart failure / W.H. Tang [et al.] // J Am Coll Cardiol. - 2002. - Vol. 39. - P. 70-78.Mineralocorticoid receptor antagonism in experimental atherosclerosis / S. Rajagopalan [et al.] // Circulation. - 2002. - Vol. 105. - P. 2212-2216.Mineralocorticoid receptor antagonism in experimental atherosclerosis / S. Rajagopalan [et al.] // Circulation. - 2002. - Vol. 105. - P. 2212-2216.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction / B. Pitt [et al.] // N Engl J Med. - 2003. - Vol. 348. - P. 1309-1321.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction / B. Pitt [et al.] // N Engl J Med. - 2003. - Vol. 348. - P. 1309-1321.Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure / S. Kasama [et al.] // J. Nucl. Med. - 2002. - Vol. 43. - P. 1279-1285.Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure / S. Kasama [et al.] // J. Nucl. Med. - 2002. - Vol. 43. - P. 1279-1285.Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface / R. A. Ahokas [et al.] // Circ Res. - 2003. - Vol. 93. - P. 124-135.Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface / R. A. Ahokas [et al.] // Circ Res. - 2003. - Vol. 93. - P. 124-135.Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension / W. B. White [et al.] // Hypertension. - 2003. - Vol. 41. - P. 1021-1026.Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension / W. B. White [et al.] // Hypertension. - 2003. - Vol. 41. - P. 1021-1026.Clin. Endocrinol / M. R. I. Williams [et al.] // J. Clin. Endocrinol. - 2002. - Vol. 86. - P. 5389-5395.Clin. Endocrinol / M. R. I. Williams [et al.] // J. Clin. Endocrinol. - 2002. - Vol. 86. - P. 5389-5395.

The authors declare that there are no conflicts of interest present.